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Abstract 
Thirty-six of 39 published calculated doubling times (Td's) of uveal melanomas ppeared to be longer than 60 
days. Metastatic death occurs 35-40 Td's after dissemination. The shortest interval between dissemination 
and metastatic death in individual patients may, therefore, be calculated as 35 x 60days = 6 years; the 
interval may extend to 80 years. This suggests, that local therapy cannot influence the survival data within the 
first 7 post-therapeutic years, because almost all metastatic deaths within these 7 years are due to pre- 
treatment dissemination. For that reason, the published comparative survival analyses after various ther- 
apies have within this period failed to show statistically significant death rates differences. 
Microscopically viable melanoma tissue has been noted in 215 of 231 histopathologically studied irradiated 
uveal melanomas. Observed mitotic figures 4-6 years after irradiation indicate retained reproductive 
integrity. This constitutes a - by enucleation avoidable - incremental risk for post-irradiation exponential 
growth and dissemination. The risk cannot become statistically manifest before a -> 10-year follow-up 
period. Retained, generally poor, visual acuity in a small percentage of patients cannot balance the 
incremental risk/benefit ratio of irradiation. A few, at present justifiable, indications for radiotherapy on 
uveal melanomas are enumerated. 
Introduction 
Management of choroidal melanomas i  still con- 
troversial. Available data have not yet definitely 
established whether enucleation or irradiation is 
more effective in prolonging life. Other undecided 
significant issues are related to vision preservation 
and posttherapeutic quality of life. For these rea- 
sons, a multicentre-controlled Collaborative Oc- 
ular Melanoma Study (COMS) has been initiated 
at 32 clinical centres throughout the United States 
and Canada in 1986 [73]. The COMS includes 1) a 
trial for patients with medium choroidal melano- 
mas which are assigned randomly to treatment by 
primary enucleation orby iodine-25 plaque irradia- 
tion; 2) a trial for patients with larger melanomas, 
assigned randomly to treatment by primary enu- 
cleation without or with preceding external beam 
irradiation, and 3) a prospective observational 
study for patients with small melanomas, treated 
according to preferences of the ophthalmologist 
and the patient. Each patient in the first two trials is 
scheduled for follow-up examination at least an- 
nually for 10 years or until death; data of the obser- 
vational study will be reviewed after a 2-year peri- 
od, to determine the appropriateness of a rando- 
mized trial for patients with small melanomas. 
The first results of cobalt-60 plaque therapy on 
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patients with uveal melanoma have been reported 
in 1959 [72]. For many years, radiotherapy received 
moderate attention, until it was postulated in 1978 
[76], that approximately two-thirds of the fatalities 
after enucleation could be attributed to dissim- 
ination of tumour emboli at the time of enuclea- 
tion. This publication stimulated interest in various 
types of conservative therapy for uveal melano- 
mas. It also aroused fundamental controversies on 
the correctness of the postulate and its recommen- 
dation not to enucleate yes with small melanomas 
[48] and on the justifiability of irradiation of uveal 
melanomas in general [24, 51, 69, 73). Brachyth- 
erapy on uveal melanomas i generally performed 
by means of applicators emitting gamma rays (co- 
balt-60, iodium-125) or beta rays (ruthenium-106). 
Teletherapy is applied by means of proton or heli- 
um ion charged particles. 
Survival statistics after enucleation cover follow- 
up periods of 10-25 years and represent all affected 
individuals. The corrected mortality rates extend 
from 40-57% [36, 48, 76]. Despite 15-20-year i ra- 
diation experience in many centres, reported sur- 
vival results after irradiation seldom have follow- 
up periods exceeding 5 years. Also, these reports 
often represent groups of patients elected accord- 
ing to varying criteria; this induces tatistical selec- 
tion artifacts, which cast doubt on their value. It is 
acknowledged [5] that the survival rate of irradia- 
ted patients has never been compared with that of 
properly matched groups of enucleated patients. 
The purposes of this review are 1) to evaluate the 
statistical consequenses of 39 published calculated 
doubling times (Td's) of uveal melanomas for the 
relevance of the so far published results of radio- 
therapy; 2) to update a previously published table 
of 43 histopathologic reports on irradiated uveal 
melanomas [51] to a table of 231 reports; 3) to 
evaluate possible influence of irradiation on surviv- 
al; 4) to summarize published post-irradiation vi- 
sual function reports and 5) to formulate on this 
basis and objective answer to the fundamental 
question when irradiation of a uveal melanoma 
may be considered a justifiable, scientifically based 
treatment. 
Consequences of calculated oubling times 
Basic oncological principles like growth rate and 
doubling time (Td) were introduced in the dis- 
cussion on the therapy of uveal melanomas by us in 
1980 [48, 49]. It was then postulated - based on 
known Td's of skin melanomas - that Td's of uveal 
melanomas with a significant component of epi- 
theloid cells might vary between 30 and 100 days, 
and Td's of spindle cell melanomas between 100 
and 365 days. Since then, 39 calculated Td's of 
uveal melanomas have been published (Table 1). 
The first report [25] concerns 1Td, calculated as 
being 17 days; this has remained the shortest uveal 
melanoma Td ever published. Two following re- 
ports [3, 29] concern 19 and 18 Td's respectively, 
which range from 22.6 to 540 days [3] and from 2 to 
135 months [29]. Both papers tress the great limi- 
tations in accurate measurement of changes in in- 
traocular tumour size. Finally [641, the Td has been 
calculated of an extremely rapidly growing melan- 
oma in a diabetic patient, in which fundus photog- 
raphy and fluorescein angiography had been per- 
formed 29 and 16 months before the eye was enu- 
cleated because of a choroidal mass, which could 
Table 1. Calculated oubling times of uveal melanomas. 
Number Follow-up Doubling time 
(Months) 
Friberg et al. (1983) 25 1 
Augsburger et al. (1984) 3 19 
Gass (1985) 29 18 
Sahel et al. (1988) 64 1 
2 17 days 
0.8-30 23-540 days 
3-170 2-135 months* 
2 64 days 
* Certain turnouts with minimal growth were presumed to be naevi. 
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not be detected on the pictures made previously. 
The Td of this rapidly growing melanoma is 64 
days. Only 3 of the 39 calculated Td's are shorter 
than 60 days. This outcome warrants the accept- 
ance, for practical therapeutic and prognostic on- 
siderations in individual patients, of a shortest pos- 
sible Td of 60 days. 
In 1956 Collins et al. [18] presented evidence, 
that death by metastasis occurs 35-40Td's after 
dissemination. This postulate - which does not 
imply the assumption that all metastases grow ex- 
ponentially from the first cell to clinical size, be- 
cause Td represents a mean value - has never been 
contradicted by others [27, 11, 47], who repeated 
and extended Collins' fundamental work. The 
shortest possible interval between dissemination 
and metastatic death for patients with a uveal mela- 
noma may, therefore, be postulated as e.g. 35 x 60 
Table 2. Histopathology of irradiated choroidal melanomas. 
Number Tumour Viable 
necrosis tumour 
Char et al. (1977) a12 4 2 4 
McFaul et al. (1980) a57 23 6 23 
Zinn et al. (1981) c77 1 1 1 
Seddon et al. (1983) c66 3 3 3 
Char et al. (1983) d13 3 2 3 
Albert (1983) c2 1 1 1 
Gass (1985) "28 5 5 4 
Schmitt (1985) e65 1 1 1 
Ferry et al. (1985) c23 1 1 1 
Guthoff et al. (1986) b33 16 107 14 
Hanssens (1986) b35 4 3 4 
Goodman et al. (1986) d3~ 1 1 1 
Lommatzsch (1986) b45 60 8? 56 
Manschot (1986) b55'56 3 2 2 
Crawford (1987) a19 27 26 26 
Daicker (1987) c21 1 1 1 
Donders (1987) d2 1 1 1 
Lee (1987) a,b42 3 1 3 
Kincaid et al. (1988) c38 5 5 5 
Fuchs et al. (1988) "'b26 8 2 8 
Lawton (1989) dl 1 1 1 
Shields et al. (1990) a'b'f'g71 59 59 52 
231 142? 215 
aCobalt-60 irradiation; bRuthenium-106 irradiation; cProton 
beam irradiation; d Helium-ion irradiation; e Strontium-90 irra- 
diation; fIridium-192 irradiation; g Iodine-125 irradiation. 
days = 6.1 years; the longest interval might at least 
be 40 x 2 years = 80 years! 
It appears accepted that metastases often tend to 
grow more rapidly than the primary tumour [58]. 
Published calculations of doubling times of uveal 
melanomas have all been based on the growth rate 
of primary tumours. The postulate on the growth 
rate of metastases of these primaries has for practi- 
cal considerations been based on a shortest primary 
Td of 60 days (see above). The mean Td repre- 
senting the great majority of all calculated Td's of 
uveal melanomas has been determined to be be- 
tween 150 and 250 days. An assumed ecrease of 
50% in the Td of melanoma metastases relative to 
the Td of the primary tumour might result in a 
metastatic Td, which would nearly always be sub- 
stantially longer than 60 days. The implicate is, that 
tumour-related death within at least 6 years after 
therapy must be due to dissemination, which oc- 
curred before therapy. A large, gradually decreas- 
ing proportion of metastatic deaths in the years 
following this 6-year period is also due to pre- 
therapeutic metastases. This implies that with iden- 
tical selection of patients no significant differences 
in survival rate can occur within the first 7-8 years 
after enucleation, various conservative therapies 
or observation only. This postulate has amply been 
confirmed by many advocates of irradiation, who 
reported absence of death rate differences already 
in 1986, in many reports during the 1987 Interna- 
tional Meeting on Intraocular Tumors and in more 
recent reports [1, 5, 8, 10, 32, 67, 69]. Non-rando- 
mized, comparative survival analyses after respec- 
tively cobalt-60 plaque therapy vs enucleation and 
proton beam irradiation vs enucleation have al- 
ready indicated that irradiation and primary enu- 
cleation are essentially equivalent in their effect on 
survival within 6--7 years after therapy [8, 67]. A 
supposed immunological impact on metastatic 
death rate has never been proved [61]. 
Histopathology of irradiated melanomas 
Table 2 illustrates that all types of radiotherapy fail 
to destroy all malignant cells in uveal melanomas: 
215 of 231 published microscopic examinations 
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(93%) mentioned viable tumour cells, while 39% 
of the tumours did not show signs of necrosis. 
These 231 melanomas may not be fully representa- 
tive for the several thousands of apparently suc- 
cessfully irradiated melanomas, but the table is 
nonetheless meaningful. The majority of these 231 
eyes have probably not been enucleated because of 
tumour egrowth, but because of irradiation dam- 
age. In 2 series of respectively 26 and 27 eyes, 19 
and 18 had been enucleated because of this damage 
and only 7 and 4 because of tumour egrowth [17, 
19]. In a series of 59 eyes, 30 had been enucleated 
because of 'regrowth or failure of the tumor to 
decrease in size' - of which no further data were 
given -, 24 because of irradiation complications 
and 5 on patient request [70]. 
It is unclear whether the histological presence of 
apparent viable tumour cells demonstrate a failure 
of radiotherapy tosterilize all tumour stem cells. It 
is certain that irradiation can have a profound ef- 
fect on the viability of uveal melanoma cells. This 
appears from a frequently encountered substantial 
and sometimes total post-irradiation turnout re- 
gression. It is to be appreciated, however, that 
regression of 50% or even 75% of the original 
turnout volume can only delay metastatic death for 
one or two Td's respectivally; it cannot prevent 
eventual death from metastases. Only total regres- 
sion may save the life of the patient, if no metasta- 
ses had been present before therapy. 
Reports on 7 proton beam irradiated eyes re- 
vealed mitotic activity in all 7 melanomas [21, 38, 
41]. The time interval between irradiation and enu- 
cleation had been more than 4 years in 3 cases. 
Presence of mitotic figures in irradiated tumour 
tissue in the first years after irradiation does not 
prove retained reproductive integrity. It has been 
shown in vitro that, although irradiated cells were 
capable of passing several cell cycles, the clonogen- 
ic cells were sterile [62, 72]. But mitoses in a tumour 
increasing in size and mitoses a number of years 
after irradiation are indicative for the presence of 
vital tumour stem cells. They indicate that irradia- 
tion not always destroys the reproductive integrity 
of all tumour stem cells as has been stated [14]. 
The 10-year-old recommendation to prevent ia- 
trogenic dissemination of melanoma cells during 
enucleation by means of two consecutive daily pre- 
enucleation doses of 400 rad on the primary tu- 
mour, sufficient o kill 90% of the tumour cells, 
might still hold true [48, 59]. Studies on pre-oper- 
atively irradiated human melanoma cells in tissue 
culture substantiate that irradiation indeed de- 
creases the attachment, growth and viability of 
melanoma cells in these cultures, while microscop- 
ic examination i dicated a reduced mitotic activity 
[7, 16, 37, 63]. No beneficial effect of pre-enuclea- 
tion irradiation could, however, be observed in 
terms of better survival after pre-enucleation irra- 
diation as compared with control groups [9, 15, 40]. 
It appears that the mean or median follow-up peri- 
ods have been 47, 37 and 35 months respectively [9, 
15, 40]. It has been explained above, that these 
periods are much too short to be of statistical rele- 
vance. 
Irradiation and survival 
It has also been explained that local therapy on 
uveal melanomas cannot influence significantly the 
survival of these patients within the first 7-8 post- 
therapeutic years. The chance of metastatic death 
within these years fully depends on the presence or 
absence of disseminated tumour cell emboli at the 
time of therapy. 
Data on survival after conservative therapy on 
uveal melanomas need two basic requirements for 
comparable statistics: 1) 10-year or longer follow- 
up periods and 2) randomisation of all patients. 
The necessity of follow-up periods of at least 10 
years has repeatedly been stressed by us [50-56]. 
This necessity has in the mean time been substan- 
tiated by calculated Td's of these tumours. 
So far, only one institution has compared meta- 
static death rates after treatment by enucleation 
and by cobalt plaque therapy after a mean follow- 
up period of 10 years [28]. Metastatic death had 
occurred in 22% of the enucleated patients and in 
57% of the irradiated ones; the median survival 
had respectively been more than 10 years and 3.8 
years. Much criticism has been expressed on this 
report, but the most relevant argument against it 
has never been raised, viz. that 10 of 12 irradiated 
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patients had died from metastasis within the first 5 
post-irradiation years. This indicates that metasta- 
ses had occurred prior to irradiation. It is disquiet- 
ing that 6 years after this first 10-year follow-up 
report none of the other centres, which have ap- 
plied radio-therapy for uveal melanomas more 
than 15 years, has so far published its 10-year sur- 
vival and functional results in all treated patients. 
Shorter follow-up periods cannot indicate survival 
advantages or disadvantages of irradiation ther- 
apy. 
The frequent survival of melanoma cells after 
irradiation, as appears from Table 2, can be ex- 
plained by 
1) a remarkable fficient repair system of melan- 
oma cells, with a greater ability to repair suble- 
thal and potentially lethal radiation damage 
than of most other tumour cells [33, 44, 73]. 
2) The often large portion of poorly oxygenated 
cells in melanomas demands high daily radi- 
ation fractions [34, 60]. 
3) In an individual patient, the radiotherapist can- 
not predict he reaction of the tumour and its 
surrounding tissue after an empirical radiation 
dose. We found absence of microscopic necro- 
sis in a choroidal melanoma in a 31-year-old 
female (lab. nr. 0.2175), 8 months after the last 
of 3 ruthenium doses, totalling 1556 Gy, which 
had been applied in 3 consecutive years [55]. In 
contrast, the eye of a 65-year-old female (lab. 
nr. 0.2278), who had received 1377 Gy rutheni- 
um in the same clinic, revealed 3 months later 
total necrosis of the melanoma nd extensive 
retinal necrosis with vitreous haemorrhages 
[56]. There is no known safe margin between 
inadequate and excessive radiation doses for 
choroidal melanomas. 
4) Current clinical methods of measurement of
intraocular tumours do not provide data which 
correspond reliably to all measurements in the 
pathology laboratory [4]. It has been found that 
the correlation between ultrasonography and 
pathological measurement of tumour thickness 
was substantially greater than that between 
clinical and pathological estimates of tumour 
basal diameters [6]. The files of the Rotterdam 
University Pathological Institute contain 4 
cases, in which margins of flat intrachoroidal 
melanoma extensions, which cannot be diag- 
nosed clinically, reach more than 10ram be- 
yond the clinically detectable tumour promi- 
nence. These basal margins are essential for 
choosing the appropriate radiation applicator, 
which seldom covers more than a 2 mm broad 
area around this prominence [17]. This might 
partly explain, why virtually all clinically mea- 
surable post-irradiation regression of choroidal 
melanomas has been in thickness and not in 
basal size of the lesion [20]. It also explains that 
eyes with tumour egrowth develop the growth 
not so much in thickness but in horizontal lat- 
eral dimensions [71]. 
The histopathologic post-irradiation findings in 
uveal melanomas (Table 2) are a strong argument 
in favor of primary enucleation of these tumours. 
This argument has recently been enforced firmly by 
a 5-year follow-up report after helium ion therapy 
and by the already mentioned microscopic study on 
59 uveal melanomas enucleated after plaque radio- 
therapy [17, 70, 71]. Standardized A-scan ultraso- 
nography revealed that 5 year after helium ion 
therapy 72% of 164 melanomas had either in- 
creased in thickness or had decreased less than 
50%, while only 8% had shrunken more than 70% 
[17]. The microscopic study on 59 plaque irradiated 
melanomas howed unequivocal mitotic cells in 
36% of the tumour residues [71]. It must be real- 
ized that exponential regrowth in such a large per- 
centage of often non-sterilized melanoma residues 
incurs an incremental risk of metastatic death for 
irradiated patients after 8 years or more. 
Preservation of vision after irradiation 
Reports on retained visual acuity after irradiation 
indicate that the 'fight for sight' principle, which is 
the main argument in favour of radiotherapy on 
uveal melanomas loses much of its authenticity 
after follow-up periods of more than 5 years. 
Table 3 presents published reports on retained 
visual function after radiotherapy. Various meth- 
ods of reporting make comparison of data hardly 
possible. The most recent report noted that visual 
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acuity decreased atleast wo lines in 84% of irradi- 
ated eyes [17]. It often declines teadily at a rate of 
approximately 10% per year [10]. About 10-15% 
of irradiated eyes retain a visual acuity of more 
than 0.1 after 5 years. Reported pinhole acuity has 
little practical value. However, even a minute acui- 
ty is better than the complete loss of vision after 
enucleation. Patients with small tumours relatively 
distant from the macular region and the optic nerve 
may have better esults. In 59% of patients with a 
pre-treatment visual acuity of at least 0.4, this acui- 
ty was retained, if the tumour was more than 3 mm 
from the central fovea and the optic nerve and if its 
height was less than 6 ram. In contrast, his vision 
was preserved inonly 16% of patients with melano- 
mas within 3 mm of these structures and a height of 
more than 6 mm. 
Conclusions 
Calculated oubling times of posterior uveal mela- 
nomas indicate that metastatic death within 6-7 
years after diagnosis of the primary turnout nearly 
always originates from pre-diagnostic metastases 
and, therefore, is independant of any locally ap- 
plied therapy on the primary uveal esion. Differ- 
ence in survival rates, observed within this period 
after various therapies, is almost certainly due to 
difference in selection of patients for treatment. 
The presence of viable melanoma tissue in 93% 
of all microscopically studied irradiated melano- 
mas, in which mitotic figures have been observed 
even 4--6 years after proton beam irradiation and in 
36% after plaque irradiation, suggests an incre- 
mental risk of metastatic death after 7-8 year post- 
irradiation period. 
Poor post-radiation visual acuity in the great ma- 
jority of patients, does not balance the incremental 
risk of post-irradiation dissemination and meta- 
static death. 
It is felt that this anticipated unfavourable risk- 
benefit ratio, which is not clearly manifest before 
follow-up periods of more than 10-year does not 
justify radiotherapy of uveal melanomas in centres, 
which do not participate in the COMS, on other 
patients than those with 1) small melanomas distant 
from the fovea and optic nerve, 2) a life expectancy 
of less than 6 years, 3) a melanoma in a single 
functioning eye and 4) patients who refuse nuclea- 
tion. 
Also for patients with small melanomas - which 
are unlikely to shed cell emboli before they have 
reached the 7 mm diameter stage [51] - the COMS 
will need a follow-up period of more than 10 years, 
before it can reach a definite conclusion concerning 
the justifiableness of as well observation as irradia- 
tion of these melanomas. Metastatic death in pa- 
tients with small melanomas occurs markedly later 
than in patients with medium sized or large tu- 
mours. 
Table 3. Preservation of vision after radiotherapy. 
Number Follow-up Preservation of vision 
Augsburger et al. (1986) 5 97 67% > 5 yrs 'large proportion patients 
will lose all useful vision' 
Seddon et al. (1986) 6s 522* median: 19 months 35% lost initial vision -> 0.1 
in 1.6 years (pinhole) 
Gragoudas et al. (1987) 31 125" median: 5.4yrs 15% < 2yrs 42% -< 0.1 (pinhole) 
Linstadt et al. (1988) 43 186 median: 26 months 51% < 0.1 
Lommatzsch et al. (1988) 46 309 -> 5 yrs 13.7% -> 0.3 
Brady et al. (1988) l~ 178 -> 5 yrs percentage vision -> 0.1 
declines + 10% per year 
Kindy-Degan et al. (1989) 39 284 mean: 30 months 12.3% > 0.1 
* Identical study population. 
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